

FOI REF: 21/117

7<sup>th</sup> April 2021

Tel: 0300 131 4500

Website: [www.esht.nhs.uk](http://www.esht.nhs.uk)

## FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

**Q1. In the past 6 months [latest 6 months available] how many patients have received the following treatments [for any disease]:**

- **Berinert (Human C1-esterase inhibitor)** 0
- **Cinryze (Human C1-esterase inhibitor)** 0
- **Takhzyro (Lanadelumab)** 0
- **Ruconest (Recombinant human C1-esterase inhibitor)** 0
- **Firazyr (Icatibant injection)** 0

**Q2. In the past 6 months [latest 6 months available] how many patients have received the following immunoglobulin treatments [for any disease]:**

- **Cuvitru** 0
- **Gammanorm** 0
- **Gamunex** 2
- **Hizentra** 0
- **Hyqvia** 0
- **Kiovig** 0
- **Octagam** 8
- **Privigen** 98
- **Subgam** 0

**Q3. In the past 6 months, how many patients attended A&E for Hereditary Angioedema (ICD10 code: D84.1) or Angioedema (ICD10 code: T78.3)? Of these patients, how many were treated with the following products:**

- **Berinert (Human C1-esterase inhibitor)** 0
- **Cinryze (Human C1-esterase inhibitor)** 0
- **Ruconest (Recombinant human C1-esterase inhibitor)** 0
- **Firazyr (Icatibant injection)** 0

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, please write to Lynette Wells, Director of Corporate Affairs, East Sussex Healthcare NHS Trust ([lynette.wells2@nhs.net](mailto:lynette.wells2@nhs.net)) quoting the above reference.

Yours sincerely

Linda Thornhill (Mrs)  
Corporate Governance Manager  
[esh-tr.foi@nhs.net](mailto:esh-tr.foi@nhs.net)